categories were reported in higher frequency in the patient-reported group compared to the physician-documented group: cardiovascular (25% vs. 20%), vascular-related (8.5% vs. 4.4%), neurologic (7.5% vs. 1.7%), gastrointestinal (30% vs. 25%), musculoskeletal comorbidities (30% vs. 21%), as well as other cancers (30% vs. 12%). Genitourinary comorbidities, including problems with urination and erectile dysfunction, were higher in the physician group (68% vs. 53%).
INTRODUCTION AND OBJECTIVES: It has been shown that transrectal ultrasound (TRUS)-guided saturation prostate biopsy (SB)
improves detection of prostate cancer (PCa) progression or risk reclassification compared to extended prostate biopsy (EB) in patients who elect for active surveillance (AS). This study aims to compare the accuracy of MRI-fusion biopsy to SB in detecting PCa reclassification in patients on AS.
METHODS: We reviewed 228 prostate biopsies from 177 patients diagnosed with PCa who elected AS. Only patients who fit the low risk NCCN criteria were included: Gleason score (GS) 6, PSA 10 ng/ml, clinical stage T1 or T2a, and percentage of positive cores 33% of total cores sampled at the time of diagnostic biopsy. Pathological progression or reclassification on surveillance biopsies was defined as no longer meeting the standard definition of low risk by Gleason score and/or disease volume.
RESULTS: The mean age of men at diagnosis was 66.7 (SD AE8.3) years. Among 228 prostate biopsies, 53 were MRI fusion biopsies and 175 were SB (! 20 cores). Disease reclassification was seen in 77/ 175 (44%) of SB and 19/53 (36%) in MRI fusion biopsies. 13 of 19 patients underwent disease reclassification detected by a combination protocol of both MRI targeted and standard biopsy, while 6/19 were reclassified by MRI targeted biopsy alone. A greater degree of disease re-classification was seen with the SB technique as compared to both targeted-only MRI-fusion targeted biopsy (44% vs. 11.3%, P<0.0001) and combined systematic and targeted MRI fusion biopsy (44% vs. 24.5%, P¼0.01). We further compared the rate of cancer progression (reclassification) at the time of each subsequent surveillance biopsy (Table 1, 2) .
CONCLUSIONS: In patients with low risk PCa who elect for AS, we demonstrated that SB might confer a better rate of detection for reclassification than protocols involving MRI fusion techniques for confirmatory or surveillance biopsies at our institution. is a viable treatment option for men with low risk prostate cancer. To date no biomarker, including PSA is able to substitute for repeat prostate biopsies to reliably monitor men for disease progression. Multiparametric MRI has emerged as the imaging modality of choice for localized prostate cancer. We studied the ability of mp-MRI to predict the outcome of repeat biopsy for men with low risk prostate cancer undergoing AS.
METHODS: We queried our IRB approved institutional database for men with prostate cancer undergoing mp-MRI. We identified all men with low or low-intermediate risk disease managed initially with AS. All men underwent mp-MRI prior to repeat prostate biopsy. Mp-MRI was analyzed for number and character of lesions by selected radiologists according to prostate imaging reporting and data system (PIRADS) version 2. Trans-rectal US guided prostate biopsies were performed with and without fusion technology depending on presence and size of visible lesions. Men with no or PIRADS 1,2 MRI lesions underwent standard template biopsies with a minimum of 12 cores including anterior zone sampling. Men with visible PIRADS 3-5 lesions underwent lesion directed, targeted biopsies along with template biopsies. Disease re-classification was defined as higher Gleason score on repeat prostate biopsy.
RESULTS: Eighty-six men diagnosed with low risk prostate cancer elected for AS and underwent mp-MRI prior to repeat prostate Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e521
biopsy. The median interval between MRI and repeat biopsy was 2.6 months. Sixty-seven percent of men (57 of 86) showed at least one PIRADS 4 or 5 lesion. CONCLUSIONS: In this prospective analysis, high biopsy Decipher scores were found in close to 1/5 of patients with low and favorable intermediate-risk disease who might be considered candidates for active surveillance. Due to heterogeneity in pathologic assessment, Decipher provides an additional objective metric for proper risk stratification prior to treatment decisions. Future studies are needed to examine the long-term outcomes in these patients, and potential changes in decision-making based on Decipher results discordant with clinical risk strata.
Source of Funding: GenomeDx Biosciences

PD28-12 EFFECTS OF INITIAL GLEASON GRADE ON OUTCOMES DURING ACTIVE SURVEILLANCE FOR PROSTATE CANCER
Selma Masic*, Samuel Washington, Janet Cowan, Hao Nguyen, Katsuto Shinohara, Matthew Cooperberg, Peter Carroll, San Francisco, CA INTRODUCTION AND OBJECTIVES: Active surveillance (AS) for low-risk prostate cancer is increasingly utilized, however, whether men with GS 3+4 disease are appropriate candidates remains a matter of debate. We evaluated the effects of the initial Gleason grade on biopsy progression, treatment and outcomes after radical prostatectomy (RP). METHODS: We prospectively followed men on AS at our institution between 1990 and 2016. Those diagnosed with Gleason 3+3 or 3+4 were included. Life tables were used to estimate progressionfree survival (progression defined as increase in Gleason grade ¼3+4 or volume >33% positive cores or >50% single core), treatment-free survival, and PSA recurrence-free survival after delayed RP. Multivariate Cox proportional hazards regression was used to determine risk factors for progression, treatment and recurrence after RP. Multivariate logistic regression was used to determine risk factors for adverse pathology (defined as Gleason ¼4+3 or stage ¼pT3b or pN1) at RP. Models were adjusted for age, race, PSA density (PSAD), total number of biopsies and percentage of cores positive at diagnosis. RESULTS: We included 1,171 men with Gleason 3+3 or 3+4 on initial biopsy and ¼1 follow-up biopsy. A total of 1,056 (91%) had Gleason 3+3 and 106 (9%) 3+4. Patients with Gleason 3+4 had lower progression-free survival (20% vs 40%, p<0.01) by any biopsy criteria and treatment-free survival (52% vs 64%, p<0.01) at 5 years. Patients diagnosed with Gleason 3+3 who upgraded were at higher risk for treatment at 5 years than those with 3+4 and no upgrade (57% vs 37%, p<0.01). Risk factors for biopsy progression were initial Gleason 3+4 pathology (HR 1.4 95% CI 1.0-1.8) and PSAD (HR 1.7 95% CI 1.5-2.0), while total number of biopsies was associated with a lower risk (HR 0.7 95% CI 0.7-0.8). PSAD was a risk factor for treatment (HR 1.9 95% CI 1.6-2.3) while total biopsies (HR 0.6 95% CI 0.6-0.7) was associated with a lower risk. Among 333 men who underwent delayed RP, there was no significant difference between diagnostic 3+4 versus 3+3 in recurrence-free survival at 3 years (80% vs 90%, p¼0.23). Gleason 3+4 at diagnosis and/or subsequent biopsy upgrade was associated with adverse pathology at RP, when controlling for age, race, PSAD, total number of biopsies and number of cores positive.
CONCLUSIONS: While Gleason 3+4 at initial biopsy is a risk factor for progression and treatment on AS and adverse pathology at RP, it is not associated with PSA relapse after RP suggesting that such patients are suitable candidates for AS. However, longer e term follow up is ongoing.
